Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment

Lymphoma complicating inflammatory bowel disease is well described. Whether the risk of lymphoma is incre‐ ased by immunosuppressive treatment with azathiop‐ rine, 6‐mercaptopurine or infliximab is a common concern among patients and physicians considering using these agents. This review aims to quantify the lymphoma risk in inflammatory bowel disease and the added risk attributable to these treatments.

[1]  Dermot Kelleher,et al.  Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low , 2000, Gut.

[2]  A. Zinsmeister,et al.  Risk of lymphoma in inflammatory bowel disease. , 2000 .

[3]  D. Palli,et al.  Hodgkin's disease risk is increased in patients with ulcerative colitis. , 2000, Gastroenterology.

[4]  J. Schwartz,et al.  Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. , 2000, Gastroenterology.

[5]  W. Bilker,et al.  Are patients with inflammatory bowel disease (IBD) at increased risk for lymphoma , 2000 .

[6]  S. Hanauer,et al.  Increased association of lymphoma and inflammatory bowel disease , 2000 .

[7]  S. Hanauer,et al.  Long-term follow-up of patients treated with infliximab (anti-TNFa antibody) in clinical trials , 2000 .

[8]  M. Kamm,et al.  Antibodies to tumour necrosis factor α as treatment for Crohn's disease , 2000, The Lancet.

[9]  B. Sands,et al.  Therapy of inflammatory bowel disease. , 2000, Gastroenterology.

[10]  L. Swinnen,et al.  Diagnosis and treatment of transplant-related lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Bickston,et al.  The relationship between infliximab treatment and lymphoma in Crohn's disease. , 1999, Gastroenterology.

[12]  S. Hanauer.  Review article: safety of infliximab in clinical trials , 1999, Alimentary pharmacology & therapeutics.

[13]  Lars Klareskog,et al.  Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study , 1998, BMJ.

[14]  G. Gores,et al.  Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. , 1998, Gastroenterology.

[15]  E. Kliewer,et al.  Diagnoses of extraintestinal manifestations and cancers in IBD in large population-based databases , 1998 .

[16]  R. Jian,et al.  Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): Long-term follow-up of patients , 1998 .

[17]  A. Zinsmeister,et al.  Risk of lymphoma in inflammatory bowel disease: A population-based estimate , 1998 .

[18]  G. Stukenborg,et al.  A potential increased risk of lymphatic and/or hematopoietic neoplasms among Crohn's disease and rheumatoid arthritis patients admitted to the university of virginia health sciences center: A four year retrospective study , 1998 .

[19]  J. Winter.  The Lymphomas , 1998, Annals of Internal Medicine.

[20]  L. Camera,et al.  [Primary ileo-cecal lymphoma mimicking Crohn's disease. Report of a case]. , 1997, La Radiologia medica.

[21]  M. Kelly,et al.  Primary intestinal Hodgkin's disease complicating ileal Crohn's disease. , 1997, The Australian and New Zealand journal of surgery.

[22]  K. Koh,et al.  Primary T-cell Lymphoma of the Colon , 1997, The Korean journal of internal medicine.

[23]  R. Ferguson,et al.  Celiac Disease and Malignancy , 1980, Journal of pediatric gastroenterology and nutrition.

[24]  Peppercom Ma.  6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come. , 1996 .

[25]  J. Sklar,et al.  Diffuse colonic mantle cell lymphoma in a patient with presumed ulcerative colitis: detection of a precursor monoclonal lymphoid population using polymerase chain reaction and immunohistochemistry. , 1996, The American journal of surgical pathology.

[26]  B. Beutler,et al.  The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.

[27]  R. Modigliani,et al.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine , 1996, The Lancet.

[28]  M. A. Peppercom.  6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come. , 1996, The American journal of gastroenterology.

[29]  A. Forbes,et al.  the risks of malignancy from either immuno‐suppression or diagnostic radiation in inflammatory bowel disease , 1995 .

[30]  B. Scallon,et al.  Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions , 1995 .

[31]  G. Kollias,et al.  The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. , 1995, Cytokine.

[32]  A. Forbes,et al.  Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. , 1995, Alimentary pharmacology & therapeutics.

[33]  J. Soulé,et al.  Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. , 1994, The New England journal of medicine.

[34]  A. Cope,et al.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. , 1994, The Journal of clinical investigation.

[35]  M. Kamm,et al.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease , 1994, The Lancet.

[36]  J. F. Fraumeni,et al.  Incidence of cancer among patients with rheumatoid arthritis. , 1993, Journal of the National Cancer Institute.

[37]  G. Mullin,et al.  Lymphoma in inflammatory bowel disease , 2010, Cancer.

[38]  D. Haller,et al.  Primary intestinal lymphoma in Crohn's disease: minute tumor with a fatal outcome. , 1992, The American journal of gastroenterology.

[39]  N. Shepherd.  Pathological mimics of chronic inflammatory bowel disease. , 1991, Journal of clinical pathology.

[40]  H. Adami,et al.  Extracolonic malignancies in inflammatory bowel disease , 1991, Cancer.

[41]  Isaacson Pg.  B cell lymphomas of mucosa associated lymphoid tissue (MALT). , 1991 .

[42]  S. Meltzer,et al.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.

[43]  N. Shepherd,et al.  Primary malignant lymphoma of the large intestine complicating chronic inflammatory bowel disease , 1989, Histopathology.

[44]  D. Sachar,et al.  Extraintestinal cancers in inflammatory bowel disease , 1985, Cancer.

[45]  P. Knekt,et al.  Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. , 1985, The American journal of medicine.

[46]  L. Kinlen.  Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. , 1985, The American journal of medicine.

[47]  P. Isaacson,et al.  Extranodal malignant lymphoma arising from mucosa‐associated lymphoid tissue , 1984, Cancer.

[48]  J. Macartney,et al.  Cancer morbidity in ulcerative colitis. , 1982, Gut.

[49]  P. Prior.  Malignancy in crohn's disease. , 1972, British journal of preventive & social medicine.

[50]  R. Morecki,et al.  Crohn disease lymph node homogenates produce murine lymphoma in athymic mice. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[51]  R. Doll,et al.  Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. , 1979, British medical journal.

[52]  B. Cooper,et al.  INTESTINAL LYMPHOMA ASSOCIATED WITH MALABSORPTION , 1978, The Lancet.

[53]  R. Hoover,et al.  Risk of cancer in renal-transplant recipients. , 1973, Lancet.

[54]  P. Peltokallio.  Chronic ulcerative colitis associated with malignant disease. , 1968, Annales chirurgiae et gynaecologiae Fenniae.

[55]  Hughes Rk.  Reticulum cell sarcoma: a case possibly originating in regional enteritis. , 1955 .

[56]  R. K. Hughes.  Reticulum cell sarcoma: a case possibly originating in regional enteritis. , 1955, The American surgeon.